In September HGS disclosed that its wound-healing agent, repifermin, had failed to heal venous ulcers in a trial of 352 patients.

FORBES: Beyond Talk

The label now includes a black box warning that it can increase the risk of death, MI, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence.

FORBES: Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp